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Abstract 
Aim: Recently, two point-of-care FIV antibody test kits (Witness and Anigen Rapid) were reported as 
being able to differentiate FIV-vaccinated from FIV-infected cats at a single time point, irrespective 10 
of the gap between testing and last vaccination (0–7 years) [1]. The aim of the current study was to 
systematically investigate anti-FIV antibody production over time in response to the recommended 
primary FIV vaccination series.  
Methods: First, residual plasma from the original study was tested using a laboratory-based enzyme-
linked immunosorbent assay (ELISA) to determine whether negative results with point-of-care 15 
testing were due to reduced as opposed to absent antibodies to gp40. Second, a prospective study 
was performed using immunologically naïve client-owned kittens and cats given a primary FIV 
vaccination series using a commercially available inactivated whole cell/inactivated whole virus 
vaccine (Fel-O-Vax FIV, three subcutaneous injections at four week intervals) and tested 
systematically (up to 11 times) over six months, using four commercially available point-of-care FIV 20 
antibody kits (SNAP FIV/FeLV Combo [detects antibodies to p15/p24], Witness FeLV/FIV [gp40], 
Anigen Rapid FIV/FeLV [p24/gp40] and VetScan FeLV/FIV Rapid [p24]).  
Results: The laboratory based ELISA showed cats from the original study vaccinated within the 
previous 0–15 months had detectable levels of antibodies to gp40, despite testing negative with two 
kits that use gp40 as a capture antigen (Witness and Anigen Rapid kits). The prospective study 25 
showed that antibody-testing with SNAP Combo and VetScan Rapid was positive in all cats two 
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weeks after the second FIV vaccination, and remained positive for the duration of the study (12/12 
and 10/12 cats positive, respectively). Antibody-testing with Witness and Anigen Rapid was also 
positive in a high proportion of cats two weeks after the second FIV vaccination (8/12 and 7/12, 
respectively), but antibody levels declined below the level of detection in most cats (10/12) by one 30 
month after the third (final) FIV vaccination. All cats tested negative using Witness and Anigen Rapid 
six months after the third FIV vaccination.  
Conclusions and relevance: This study has shown that a primary course of FIV vaccination does not 
interfere with FIV antibody-testing in cats using Witness and Anigen Rapid, provided primary 
vaccination has not occurred within the previous six months. Consequently, Witness and Anigen 35 
Rapid antibody test kits can be used reliably to determine FIV infection status at the time of annual 
booster vaccination to help detect ‘vaccine breakthroughs’ and in cats that have not received a 
primary course of FIV vaccination within the preceding six months. The duration of antibody 
response following annual booster FIV vaccination and the resulting effect on antibody testing using 
point-of-care kits needs to be determined by further research. The mechanism(s) for the variation in 40 
FIV antibody test kit performance remains unclear. 
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Introduction 
Feline immunodeficiency virus (FIV) can infect domestic cats and may cause, after a long 45 
asymptomatic phase, variable clinical disease due to its immunosuppressive and oncogenic 
properties [2,3]. A FIV vaccinea, released for use in domestic cats (2002 in the USA; 2004 in 
Australia), was used as a ‘proof of concept’ for the development of sterilizing immunity against 
lentiviruses, including human immunodeficiency virus (HIV-1) [4-6]. However, the vaccine wasn’t 
registered in many jurisdictions (e.g. Europe), owing in part to concerns related to the production of 50 
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antibodies in FIV-vaccinated cats indistinguishable from those produced in response to natural FIV 
infection, such antibodies being the target for all point-of-care test kits [7]. Recently, we showed 
that some FIV antibody detection kits could differentiate FIV-vaccinated and FIV-infected cats under 
field conditions, reinforcing the complexity of antibody responses that occurs following FIV 
vaccination [1,8]. 55 
The FIV genome is composed of approximately 9,500 nucleotides, comprising three main open 
reading frames (gag, pol and env)  encoding major capsid proteins (MA, matrix, p15; CA, capsid, p24; 
NC, nucleocapsid, p7), viral enzymes (PR, protease; RT, reverse transcriptase; IN, integrase) and 
envelope glycoproteins (TM, transmembrane, gp40; SU, surface, gp120), respectively [9]. Areas of 
the genome capable of evoking host antibody response (B-cell epitopes) have been identified in the 60 
p15, p24, p7, gp40 and gp120 domains, with immunodominant epitopes located in the highly 
variable region (V3) of gp120 [4,10].  A cascade of antibody responses occurs following natural FIV 
infection, with antibodies to p24 and gp40 detectable within three weeks of infection and antibodies 
to p15 detectable within four weeks of infection using Western blot analysis [8,11]. Antibody 
production in FIV-infected cats persists for life, although antibody levels (particularly to p15 and p24) 65 
may wane in the terminal stage of infection [4]. The complex nature of this antibody cascade has 
resulted in variable definitions of FIV positivity based on Western blots, including (i) presence of 
antibodies to gp120, (ii) antibodies to gp120 and at least one core protein (p7, p15, or p24); (iii) 
antibodies to at least two core proteins; or (iv) antibodies to three core proteins [11,12]. 
The only commercial FIV vaccine (Fel-O-Vax FIV) available consists of formalin-inactivated whole 70 
cells (IWC) and whole virus (IWV) suspended together in an adjuvant [5]. It was presumed, on the 
basis of this composition, that the antibody response of FIV-vaccinated cats would be 
indistinguishable from those of FIV-infected cats [13]. However, by using three point-of-care 
antibody tests detecting antibodies to different target FIV antigens, it was shown that FIV-
vaccinated/FIV-uninfected cats consistently tested seropositive with SNAP FIV/FeLV Combo (p15 & 75 
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p24), but seronegative with Witness FeLV/FIV (gp40) and Anigen Rapid FIV/FeLV (p24 & gp40) for 0 
to 7 years following FIV vaccination. Consequently, there was speculation that p15 retains 
immunogenicity during FIV vaccine production to a greater extent than p24 or gp40 [1]. This finding 
was questioned by another researcher, who used only Witness kits and a small cohort of kittens (n = 
19) given a primary FIV vaccination series not in accordance with the manufacturer’s 80 
recommendations (two injections administered instead of three), with a high FIV false-positive rate 
reported using Witness [14]. Another larger study (n = 104), however, confirmed the ability of the 
Witness and Anigen Rapid kits to differentiate FIV-vaccinated and FIV-infected cats, but poor results 
from a fourth test kit that only detects antibodies to p24 (VetScan FeLV/FIV Rapid) challenged the 
notion that the ability of test kits to differentiate is solely linked to the choice of FIV antigen for 85 
antibody capture [15]. Further work is therefore required to precisely and prospectively determine 
the antibody response following FIV vaccination in relation to point-of-care test kit methodology. 
The aims of the current study were (i) to determine if FIV-vaccinated cats produce antibodies to 
gp40 at concentrations below the detection threshold of Witness FeLV/FIV and Anigen Rapid 
FIV/FeLV kits, using a laboratory well-based enzyme-linked immunosorbent assay (ELISA); and (ii) to 90 
investigate semi-quantitatively the duration of antibody response to p15, p24 and gp40 in cats 
following a primary course of FIV vaccination using four point-of-care FIV antibody test kits (SNAP 
FIV/FeLV Combo, Witness FeLV/FIV , Anigen Rapid FIV/FeLV and VetScan FeLV/FIV Rapid). 
                                                          
a Fel-O-Vax® FIV, Boehringer Ingelheim, Fort Dodge, IA, USA. 
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Material and methods 
Sample Population (Study 1) 95 
Residual blood from Westman et al. (2015) was utilized for the first arm of this study [1]. A total of 
118 FIV-vaccinated cats had been recruited, comprising 4 FIV-infected and 114 FIV-uninfected cats. 
The median age of these cats was seven years (range 2–18 years, interquartile range [IQR] 5–10 
years) and the procedure for final assignment of FIV status, which included a combination of 
antibody testing, polymerase chain reaction (PCR) testing and occasionally virus isolation, was 100 
previously described [1]. All 118 cats had received a primary course of FIV vaccination consisting of 
three vaccines 2–4 weeks apart, in accordance with the manufacturer’s recommendations, and a 
minimum of two annual booster vaccines, with no more than 15 months gap between annual 
vaccinations. 110/118 had received three or more annual boosters. Most cats (105/118) had been 
vaccinated within one year of sampling, and all cats had been vaccinated within 15 months of 105 
sampling (range 2–443 days, median 215 days, IQR 126–308 days) (Figure 1). Seven cats from the 
original study overdue for their annual FIV vaccination by 3–7 years were not tested [1]. Of the 114 
FIV-uninfected cats, 114 had tested FIV-positive with SNAP Combo, six with Witness and zero with 
Anigen Rapid. Each cat was only available for sampling at a single time point, although occasionally a 
discordant cat had subsequent follow-up testing. A total of 23 FIV-unvaccinated/FIV-infected cats 110 
from the original study, determined by antibody and PCR testing and comprising a median age of six 
years (range 3–16 years, IQR 5–10 years), were also tested [1]. Plasma stored at -80oC was 
transported on ice to Veterinary Diagnostic Services, The University of Glasgow for a laboratory-
based gp40 ELISA. Approval was granted by The University of Sydney Animal Ethics Committee 
(Approval number N00/1-2013/3/5920). 115 
 
Sample Population (Study 2) 
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Four FIV-unvaccinated/FIV-uninfected kittens (< 6 months-of-age) and 12 FIV-unvaccinated/FIV-
uninfected cats (> 6 months) were recruited from two veterinary clinics and two animal shelters in 
Sydney, Australia. The median age of all recruited cats was two years (range 0.3–8 years, IQR 1–4 120 
years), significantly younger than cats in Study 1 (P < 0.001; Mann-Whitney U-test). Recruited cats 
were given a primary course of three FIV vaccines subcutaneously, four weeks apart (weeks 0, 4 and 
8), in accordance with the manufacturer’s recommendations, and antibody-tested regularly (up to 
11 times) using four rapid FIV antibody test kits for 34 weeks (238 days; Table 1). Antibody testing at 
weeks 14, 16 and 20 was only pursued in cats that tested FIV-positive with Witness or Anigen Rapid 125 
at the previous sampling, given the high likelihood of negative results with Witness/Anigen Rapid 
and positive results with SNAP Combo/VetScan Rapid in the other cats; one of these cats was lost to 
follow-up and unable to be tested at weeks 16 and 20. PCR testing was performed by a commercial 
laboratory (FIV Real PCR)b at the start of the study (week 0; prior to primary FIV vaccination 
commencing), and at the end of the study (week 34), to ensure FIV infection had not occurred during 130 
the course of vaccinations and period of antibody-testing.  
Owners were offered free FIV testing and vaccination in return for enrolling their cat in the study. 
Cats were housed with their owners for the duration of the study; outdoor access was not regulated 
and was at the owners’ discretion. One cat tested FIV-positive with an antibody test kit at week 0 
(Anigen Rapid)c and was ultimately withdrawn at the conclusion of the study owing to uncertainty 135 
regarding its FIV status, and three other cats were withdrawn during the study for various reasons 
unrelated to blood sampling or FIV vaccination (one cat was hit by a car and died between week 0 
and week 2; one was withdrawn at the owner’s request after week 4 due to transport difficulties; 
and one cat was euthanased by the shelter after week 20 as the cat was re-surrendered following an 
incident of human-directed aggression at home). All cats tested FeLV-negative with the four kits. 140 
Approval was granted by The University of Sydney Animal Ethics Committee (Approval number 
N00/1-2015/858). 
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Detection of antibodies to gp40 using a laboratory ELISA 
A peptide ELISA, using a nine amino acid sequence (CNQNQFFCK)d from the highly conserved 145 
immunodominant TM2 domain of gp40, was used to detect antibodies [16]. Plasma samples were 
first complement inactivated by incubating at 56oC for 30 min. The wells of 96-well microtitre platese 
were coated with 250 ng/well of lyophilized gp40 epitope,f diluted in sodium carbonate bicarbonate 
binding buffer (0.2M anhydrous sodium carbonate, 0.2M sodium carbonate and deionized water at a 
ratio of 1:11.5:4, respectively). The plates were incubated at 4oC overnight whilst being agitated at 150 
30 rpm. The following day the wells were aspirated and washed five times with 200 µL of phosphate 
buffered saline (PBS) supplemented with 0.1% Tween (PBST). Unabsorbed sites were blocked 
following incubation with 200 µL of 2% low fat milk powder in PBST (MP/PBST) for one hour at room 
temperature. The wells were then aspirated and washed five times with 200 µL of PBST, and 100 µL 
of plasma added to the wells at a dilution of 1/200 (MP/PBST). The plates were sealed and incubated 155 
at room temperature for one hour before being washed five times with 200 µL of PBST, after which 
100 µL of biotinylated goat anti-cat secondary antibodyg was added to each well at a dilution of 
1/1000 (MP/PBST). The plates were sealed and incubated at room temperature for one hour. Wells 
were then aspirated and washed five times with 200 µL of PBST, and 100 µL of horseradish 
peroxidase conjugated to streptaviding added to each well at a dilution of 1/1000 (MP/PBST). The 160 
plates were sealed and incubated at room temperature for 20 min, aspirated and washed five times 
with 200 µL of PBST, and then 100 µL of 3’,3’,5’,5’-tetramethylbenzidine liquid (TMB)h added to each 
well. Plates were again sealed and incubated at room temperature for 30 min before being read at 
650 nm using a microplate readeri and optical density (OD) values recorded. Positive and negative 
controls were included on each test plate. The positive control plasma was collected from a cat, 165 
infected experimentally with the biological isolate of FIVGL8, which tested FIV-positive by Western 
blot and virus isolation. The negative control plasma was collected from an uninfected, specific 
pathogen free cat that had been confirmed FIV-negative by Western blot and virus isolation. ELISA 
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results were not categorised as ‘positive’ or ‘negative’, but rather the range of antibody responses 
against gp40 were compared amongst the FIV-vaccinated cats tested. 170 
 
Detection of antibodies using FIV point-of-care test kits   
Blood was collected via jugular or cephalic venipuncture and stored in an EDTA tube at 4oC. FIV 
antibody-testing was performed using four commercially available point-of-care kits within 24 hours 
of sampling, in accordance with the manufacturers’ recommendations. The kits tested were SNAP 175 
FIV/FeLV Combo,j Witness FeLV/FIVk, Anigen Rapid FIV/FeLVl and VetScan FeLV/FIV Rapid.m SNAP 
Combo is a lateral-flow ELISA kit while the other three kits use immunochromatography to detect 
different FIV antibodies (Table 2). The fourth kit (VetScan Rapid) was added to the three kits tested 
in a previous study [1] to include a methodology detecting antibodies to p24 alone. The results panel 
for each cat was photographed digitally at the time of testing. It is important to note that all four kits 180 
are marketed for the diagnosis of FIV infection, rather than the detection of antibodies produced in 
response to FIV vaccination as used in the current study. 
 
Statistical analysis 
Numerical analyses were performed at the conclusion of the study using statistical software (Genstat 185 
16th Edition).n Significance was considered at P < 0.05. A Shapiro-Wilk test was used to assess data 
for normality; since data was not normally distributed (age of cats in Study 1 and Study 2, days post 
FIV vaccination in Study 1 and gp40 ELISA OD values) medians were reported and Mann-Whitney U-
tests used for comparisons. ANOVA testing was used on loge transformed data to compare gp40 
ELISA OD values grouped according to months since last annual FIV vaccination (0–3, 3–6, 6–9 and 190 
9–15 months), number of annual booster FIV vaccinations administered (2–8) and age of cat at 
testing (grouped < 5 years, 5–10 years, > 10 years). Simple linear regression modelling was also 
performed with loge OD values as the outcome and days since last annual FIV vaccination, or age of 
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cat at testing, as explanatory variables. Multivariate regression modelling was performed to consider 
the combined effect of days elapsed since last vaccination and number of annual booster 195 
vaccinations administered. 
                                                          
b IDEXX Laboratories, East Brisbane, Queensland, Australia. 
c This cat was inexplicably FIV-negative on PCR testing at week 0 and week 34, and remained FIV-positive with 
Anigen Rapid throughout the 34 weeks. Antibody-testing at week 0 was negative with SNAP Combo, Witness 
and VetScan Rapid.  
d Cysteine-asparagine-glutamine-asparagine-glutamine-phenylalanine-phenylalanine-cysteine-lysine 
e Immulon 2 HB, Thermo Fisher Scientific, Waltham, MA, USA. 
f AltaBioscience, Birmingham, UK. 
g Vector Laboratories, Peterborough, UK. 
h TMB Super Slow, Sigma Aldrich, St. Louis, MO, USA. 
i MultiSkan Ascent Plate Reader (spectrophotometer), MTX Lab Systems, Bradenton, FL, USA. 
j IDEXX Laboratories, Westbrook, ME, USA. 
k Zoetis Animal Health, Lyon, France. 
l BioNote, Gyeonggi-do, Korea. 
m Abaxis, Union City, CA, USA 
n GenStat 16th Edition for Windows, VSN International, Hemel Hempstead, United Kingdom. 
 
Results 
FIV gp40 laboratory quantitative ELISA (Study 1) 
FIV-infected cats tested positive for antibodies recognising gp40, irrespective of FIV vaccination 200 
status (P < 0.001 compared to [cf:] negative control). FIV-unvaccinated/FIV-infected cats showed a 
similar antibody response to the positive control (P = 0.20), as expected, while FIV-vaccinated/FIV-
infected cats showed a weaker antibody response compared to the positive control (P = 0.01). No 
significant difference in the magnitude of antibody response was observed between FIV-
unvaccinated/FIV-infected and FIV-vaccinated/FIV-infected cats (P = 0.07) (Figure 2A). FIV-205 
vaccinated/FIV-uninfected cats that tested FIV true-negative with Witness kits in the original study (n 
= 108) also tested antibody positive (P < 0.001 cf: negative control), but antibody levels for these 
cats were lower than in FIV-infected cats (P < 0.001). FIV-vaccinated/FIV-uninfected cats that tested 
FIV false-positive with Witness kits in the original study (n = 6) tested antibody positive (P < 0.001 cf: 
negative control), with higher antibody levels compared to the 108 Witness true-negative cats (P < 210 
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0.001). This distinction, however, was not clear-cut; for example, the upper range of the 108 Witness 
true-negative cats encompassed the six Witness false-positive cats apart from one individual (Figure 
2A). When time since last vaccination was analysed as a potential factor in the antibody response of 
the 114 FIV-vaccinated/FIV-uninfected cats, no significant effect was found (P = 0.42 [days], P = 0.07 
[grouped by month]) (Figure 2B). When age of cat at testing was considered as a possible factor 215 
affecting the antibody response of the 114 FIV-vaccinated/FIV-uninfected cats, no significant effect 
was found (P = 0.21 [years], P = 0.20 [grouped by category < 5, 5–10, > 10 years]) (Figure 2C). There 
was no significant difference in antibody response when cats were grouped according to the number 
of annual FIV vaccinations administered (P = 0.43; Figure 2D). Similarly, when the time since the last 
vaccination and the number of annual vaccinations were considered together, no significant effect 220 
was observed (P ≥ 0.61). 
FIV point-of-care testing (Study 2) 
Sixteen cats commenced the study and were vaccinated against FIV, with 12/16 cats completing the 
study. Table 3 provides a summary of results for these 12 cats.  Online Supplement 1 provides a 
summary of results for all 16 cats (i.e. including the 4 exclusions), online Supplement 2 results for 225 
kittens < 6 months-of age  (n = 4) and online Supplement 3 results for cats > 6 months (n = 8). 
Considering the 12 cats, FIV antibodies were detected as early as two weeks after the first 
vaccination using SNAP Combo and Witness, and as early as four weeks using Anigen Rapid and 
VetScan Rapid. Two weeks after the second vaccination (week 6), all cats (12/12) tested FIV-positive 
with SNAP Combo and VetScan Rapid, 8/12 (67%) tested FIV-positive with Witness and 7/12 (58%) 230 
tested FIV-positive with Anigen Rapid. At the completion of the study, six months after the third 
vaccination (week 34), all cats (12/12) were FIV-positive with SNAP Combo, two cats had become 
FIV-negative with VetScan Rapid and all cats were FIV-negative with Witness and Anigen Rapid 
(Figure 3). 
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Three cats were tested between weeks 14 and 20 as a consequence of testing FIV-positive with 235 
Witness and/or Anigen Rapid at week 12: 
(i) One cat tested FIV-positive with Witness at week 12 and 14, then was lost to follow-up until week 
34 when it tested FIV-negative with Witness. 
 (ii) One cat tested FIV-positive with Witness and Anigen Rapid at week 12, 14, and 16, but FIV-
negative with both kits at week 20; 240 
(iii) One cat tested FIV-positive with Anigen Rapid at week 12 and 14, but FIV-negative using this kit 
at week 20; 
 
Discussion 
The complexity of the antibody response following vaccination with a commercial IWC/IWV FIV 245 
vaccine was further described in this study. Laboratory-based ELISA quantification of antibodies to 
gp40 (Study 1) demonstrated FIV-vaccinated cats had a detectable humoral response to gp40 for at 
least 15 months after FIV vaccination, despite a gp40 point-of-care test kit (Witness) testing negative 
in 95% of these  samples (108/114) [1]. It was surprising not to find a quantitative decrease in gp40 
antibody concentration over time since last FIV vaccination as determined by the ELISA OD value, 250 
especially when the Witness results from the second arm of the study (Study 2) were considered. 
The explanation for this is unknown, and may relate to the older age of cats in Study 1 compared to 
Study 2 as well as reduced immunogenicity of the FIV vaccine with repeated booster vaccinations. 
Serial antibody-testing using four different kits showed that six months after a primary course of FIV 
vaccines was administered, Witness FeLV/FIV and Anigen Rapid FIV/FeLV tested FIV-negative in 255 
100% of cats, while SNAP FIV/FeLV Combo and VetScan FeLV/FIV Rapid tested FIV-positive in 100% 
and 83% of cats, respectively. 
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At first glance, the gp40 antibody results from Study 2 and the original study [1] appear 
contradictory. Study 2 found that a finite proportion of immunologically naïve cats administered a 
primary course of FIV vaccination produced levels of antibodies to gp40 detectable by Witness for up 260 
to six months following vaccination, yet the original study found a very low level of false-positive FIV 
results with Witness (6/114) in a cohort of cats vaccinated against FIV annually for at least two years, 
including a false-positive rate of only 1/16 in recently inoculated cats (vaccinated within the previous 
12 weeks). Results obtained from the current study with Witness testing were similar to results 
obtained by another group who concluded that Witness testing alone could not be relied on to 265 
distinguish natural FIV infection and FIV vaccination shortly after a primary vaccination course [14]. 
In that study (Lappin 2015), it was reported that 100% of FIV-vaccinated cats during their primary 
course tested FIV-positive with Witness four weeks after the second FIV vaccination, 50% tested FIV-
positive five weeks after the second vaccination and 0% tested FIV-positive 30 weeks after the 
second vaccination. There was a high dropout rate, however; of the 19 kittens that were enrolled, 270 
only four kittens were tested at four weeks, eight kittens were tested at five weeks and 11 kittens 
were at 30 weeks post-vaccination. Furthermore, only two FIV vaccinations were administered to 
kittens (instead of the recommended three), which made the results more difficult to interpret [14]. 
A similar longitudinal study to the current design is required in adult cats prior to and following 
annual vaccination to determine whether this period of detectable antibody response extends 275 
beyond primary vaccination. 
The explanation for this seeming discrepancy with Witness testing is possibly two-fold. Firstly, some 
studies have reported a lower antibody response in people being re-vaccinated compared to those 
being vaccinated for the first time. Govaert and colleagues found older people (> 60 years) re-
vaccinated with an inactivated influenza vaccine had a ‘strikingly’ lower humoral immune response 280 
compared to people who had not previously been vaccinated [17]. A longitudinal study of elderly 
people (56–79 years) administered a primary pneumococcal polysaccharide vaccine, and given a 
booster vaccination six years later, found the antibody titres after re-vaccination were about half the 
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titres after primary vaccination [18]. The trend for a weaker antibody response following booster 
vaccination compared to primary vaccination, however, is not steadfast; for example, one study that 285 
investigated the vaccine-induced antibody response against hepatitis virus B in people reported 
higher antibody levels following booster vaccination compared to at the end of the primary 
vaccination course six years earlier [19]. Factors related to the nature of the pathogen and the 
antigen(s) and adjuvants presented during vaccination are likely to play a crucial role in determining 
the ongoing humoral response. Secondly, age may be a factor; cats recruited for the original 290 
Westman et al. (2015) study (which became the cats in Study 1) were substantially older than cats in 
Study 2 (median age 7 versus 2 years; P < 0.001) due to the large proportion of kittens (4/12). 
Likewise, Lappin (2015) tested only kittens [14]. Duration of immunity (DOI) studies are sparse in the 
veterinary literature, and most are only concerned with protection from challenge rather than 
antibody quantitation for diagnostic purposes [20]. Flow cytometry studies have demonstrated an 295 
age-related remodeling of the immune system in cats, with a gradual decline in relative percentage 
of lymphocytes [21], and an absolute reduction in B-cells in senior cats (10–14 years) compared to 
young cats (2–5 years) [22]. DOI studies are more common in the human literature, where it is 
generally accepted that older people have a weaker humoral response following vaccination than 
younger people. For example, one study investigating antibody response in people administered an 300 
inactivated H1N1 vaccine found pre- and post-vaccination titres were generally lower in the elderly 
(> 70 years-of-age) than the young (< 30 years) [23]. We postulate that the accuracy of the Witness 
kit to correctly assign FIV infection status in FIV-vaccinated cats reported previously may be 
explained by a relatively low level of gp40 antibodies in older cats following booster FIV vaccination, 
compared to the younger cats in both Study 2 and the study reported by Lappin that were 305 
vaccinated against FIV for the first time. Contrary to this theory is the absence of a trend in Study 1 
for gp40 antibody concentration to diminish with increased age of cat at testing and/or number of 
annual FIV booster vaccinations administered (Figures 2C and 2D), nor was there a noticeable trend 
for kittens to test false-positive with Witness more often than adult cats in Study 2 (online 
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Supplements 2 and 3). Inadequate sample sizes for both studies may have been responsible. To 310 
further investigate the role of age and re-vaccination, we plan to monitor cats in Study 2 for several 
years and determine their gp40 antibody response following booster FIV vaccination, to see if the 
antibody response following annual vaccination is less than their antibody response following initial 
(primary) vaccination. 
Sequential semi-quantitative antibody testing following FIV vaccination with Witness and Anigen 315 
Rapid showed peak antibody production occurred during and shortly after a primary course of FIV 
vaccination (three injections at four week intervals). Two weeks after the second vaccination (week 
6), 67% (8/12) and 58% (7/12) cats tested seropositive for FIV antibodies using Witness and Anigen 
Rapid, respectively. By four weeks after the third vaccination (week 12), only 17% (2/12) cats tested 
seropositive with Witness or Anigen Rapid, and by six months after the third vaccination (week 34) 320 
p24 and gp40 antibody levels had decreased below the detection limit for both kits. Peak antibody 
production to p24 and gp40 six to 12 weeks after the first primary FIV vaccination (in a series of 
three), as demonstrated by these results, supports results from previous studies, including results 
from p24 ELISA determinations in experimental kittens vaccinated three times 2-3 weeks apart 
(unpublished data, Boehringer Ingelheim). Using laboratory-based ELISA testing, Huang and 325 
collaborators showed antibody against p24 and gp40 peaked 1–3 weeks after the third primary FIV 
vaccination (vaccines given three weeks apart) in kittens and decreased over the following three 
months, with antibody levels maintained for 12 months in most cats [24,25]. The same result was 
found by another group using ELISA testing for antibodies to whole FIV antigen and recombinant p24 
(r-gag) in cats aged 7–12 months [26]. Western blot analysis of four FIV-vaccinated cats confirmed 330 
antibody production to p15, p24 and gp40 three weeks after second vaccination, which persisted for 
at least 12 months following third vaccination [13]. The reason why ELISA gp40 testing in the current 
study (Study 1) did not show a peak (and subsequent fall) in antibody production according to time 
elapsed since last vaccination (Figure 2B), similar to ELISA testing by Huang et al. and Kusuhara et al., 
15 
 
is uncertain. It may also relate to a reduced antibody response in older cats following annual booster 335 
FIV vaccination, rather than younger cats receiving a primary course of FIV vaccination [17,23]. 
Our results confirmed that care needs to be exercised in the period immediately following primary 
FIV vaccination using Witness and Anigen Rapid, with false-positive FIV results occurring using both. 
In light of these findings, we suggest an amendment to our previous conclusion [1] and recommend 
that antibody testing to detect FIV infection in FIV-vaccinated cats is reliable using Witness and 340 
Anigen Rapid, providing primary vaccination against FIV has not occurred within the preceding six 
months. As discussed above, more research needs to be performed to investigate whether this 
recommendation also applies to cats receiving annual booster FIV vaccinations. In a shelter situation, 
where large scale FIV screening is being undertaken, it is highly unlikely cats will have received a 
primary FIV vaccination series in the preceding six months as FIV vaccination rates are generally low, 345 
and cats so vaccinated are generally well cared for and less likely to be surrendered to a shelter 
facility [27]. Transient antibody production for up to six months after primary FIV vaccination is also 
not relevant when testing cats for FIV vaccine breakthrough immediately prior to the next annual FIV 
vaccination booster. If a positive FIV-antibody result is obtained in a cat where recent primary 
vaccination is possible, submitting seropositive specimens for confirmatory FIV PCR testing is 350 
recommended. A negative FIV test result with either Witness or Anigen Rapid remains robustly 
reliable and is recommended as the screening test of choice, except in cases of recent infection, 
when repeat testing two months later is recommended [28]. 
Results from sequential antibody testing in this study challenge our previous notion that p15 is more 
immunogenic than p24 and gp40 in the FIV vaccine. SNAP Combo (which detects antibodies to both 355 
p15 and p24) gave a seropositive result in 12/12 vaccinated cats from six weeks after the first FIV 
vaccination and all 12 cats remained FIV-positive for the duration of the study (34 weeks). 
Additionally, VetScan Rapid (which detects antibodies to p24 but not p15) tested seropositive in 
12/12 vaccinated cats from six weeks after the first FIV vaccination and 10/12 (83%) remained FIV-
16 
 
positive at the end of the study. If the difference in performance between SNAP Combo and 360 
Witness/Anigen Rapid was solely attributable to p15 being more immunogenic in the FIV vaccine, 
then VetScan Rapid would have performed comparably to Witness/Anigen Rapid. The differing 
performance of VetScan Rapid infers that the difference in kit performance may rely more on factors 
related to testing methodology (e.g. ELISA versus immunochromatography, the antibody threshold 
at which the test is set and how the capture antigen is  prepared) than factors related to the FIV 365 
vaccine (i.e. immunogenicity of different epitopes). For this reason, care must be taken when 
selecting an appropriate antibody kit to avoid false-positive results in FIV-vaccinated cats. Our 
findings cannot be extrapolated to other antibody kits without testing being performed. Future 
research should ideally quantitate the antibody response directed against each epitope (p15, p24 
and gp40) over time, using a common methodology for each (e.g. ELISA testing), to further 370 
understand the breadth, magnitude and duration of the antibody cascade following FIV vaccination. 
Conclusion 
The complexity of antibody production following FIV vaccination was further described using both 
laboratory-based ELISA and an extended range of point-of-care testing kits. Antibodies to p15, p24 
and gp40 were detectable early (within four weeks of the first FIV vaccination) using various test kits. 375 
SNAP Combo and VetScan Rapid tested persistently FIV-positive for six months in cats given a 
primary course of FIV vaccination, while Witness and Anigen Rapid tested FIV-negative in all cats by 
six months following primary FIV vaccination. The limit of detection at which these antibody kits are 
calibrated appears to be the critical factor, since antibodies to gp40 (and likely p15 and p24) persist 
for at least 15 months after FIV vaccination and kits that are biased towards sensitivity (e.g. SNAP 380 
Combo, VetScan Rapid) will detect these antibodies in addition to those produced by natural FIV 
infection. In jurisdictions where FIV vaccination is practiced, testing for potential FIV break-through 
infection prior to annual FIV vaccination is prudent [29]. In this setting, Witness and Anigen Rapid 
17 
 
are the FIV antibody test kits of choice since fewer false-positive results would be anticipated 
compared to the SNAP Combo and VetScan Rapid tests. 385 
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Table 1: Outline of the prospective study design (Study 2), showing time points for three FIV 
vaccinations (weeks 0, 4 and 8), PCR testing (weeks 0 and 34) and antibody-testing (up to 11 times 
between week 0 and 34). Antibody-testing was not performed at weeks 14, 16 or 20 for cats that 
were FIV-negative at week 12 with Witness and Anigen Rapid. 490 
Table 2: FIV target antigen for the antibodies detected using the four different point-of-care FIV 
antibody kits tested in Study 2. 
aSNAP FIV/FeLV Combo sold in Europe has an additional target antigen (gp40) included. 
Table 3: Summary of FIV PCR and FIV antibody test results from the prospective study (Study 2) at 
various time points (n = 12). Four cats were withdrawn from the study (see text for details); results 495 
from these cats are not included here but are provided in online Supplement 1. 
 
Figure 1: Categorization of FIV-uninfected cats from Study 1 based on time (days) elapsed since last 
FIV vaccination (n = 114). Of the 114 FIV-uninfected cats, 114 had tested FIV-positive with SNAP 
Combo, six with Witness and zero with Anigen Rapid. The six FIV false-positive results obtained with 500 
Witness occurred at the following intervals after FIV vaccination: 0–30 days (1), 121–150 days (1), 
181–210 days (1), 241–270 days (1) and 331–360 days (2). 
Figures 2A-D: Results from ELISA testing for antibodies recognising FIV gp40 peptide (Study 1). 
Positive and negative controls are shown. The optical density (OD) is displayed on the y-axis. Mean 
and SEM bars are shown. 505 
Figure 2A: FIV-vaccinated/FIV-infected cats (n = 4), FIV-vaccinated/FIV-uninfected cats (FIV false-
positive with Witness, n = 6) and FIV-vaccinated/FIV-uninfected cats (FIV true-negative with Witness, 
n = 108).  
*represents significant difference (P < 0.01) between groups of cats. 
Figure 2B: FIV-vaccinated/FIV-uninfected cats (n = 114) according to the time (days) elapsed since 510 
the last annual FIV vaccination. No significant effect was found (P = 0.42). 
Figure 2C: FIV-vaccinated/FIV-uninfected cats (n = 114) according to the age of cat at the time of 
sampling (years). No significant effect was found (P = 0.21). 
Figure 2D: FIV-vaccinated/FIV-uninfected cats (n = 114) according to number of annual booster FIV 
vaccinations received. No significant effect was found (P = 0.43). 515 
Figure 3: Summary of FIV antibody test results from the prospective study (Study 2) at various time 
points (n = 12). The FIV target capture antigen/s for each point-of-care antibody test kit is included in 
brackets. A primary FIV vaccination course was administered at 0, 4 and 8 weeks. 
 
 520 
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Online Supplement 1: Summary of FIV PCR and FIV antibody test results from the prospective study 
(Study 2) at various time points (n = 16), including four cats withdrawn from the study at various 
time points (after weeks 0, 4, 20 and 34). 
Online Supplement 2: Summary of FIV PCR and FIV antibody test results from the prospective study 
(Study 2) at various time points for kittens < 6 months-of-age (n = 4). 525 
Online Supplement 3: Summary of FIV PCR and FIV antibody test results from the prospective study 
(Study 2) at various time points for cats > 6 months-of-age (n = 8). 
Figure 1: Categorization of FIV-uninfected cats from Study 1 based on time (days) elapsed since last FIV 
vaccination (n = 114). Of the 114 FIV-uninfected cats, 114 had tested FIV-positive with SNAP Combo, six 
with Witness and zero with Anigen Rapid. The six FIV false-positive results obtained with Witness 
occurred at the following intervals after FIV vaccination: 0–30 days (1), 121–150 days (1), 181–210 days 
(1), 241–270 days (1) and 331–360 days (2). 
 
Figures 2A-D: Results from ELISA testing for antibodies recognising FIV gp40 peptide (Study 1). Positive 
and negative controls are shown. The optical density (OD) is displayed on the y-axis. Mean and SEM bars 
are shown. 
Figure 2A: FIV-vaccinated/FIV-infected cats (n = 4), FIV-vaccinated/FIV-uninfected cats (FIV false-positive 
with Witness, n = 6) and FIV-vaccinated/FIV-uninfected cats (FIV true-negative with Witness, n = 108).  
*represents significant difference (P < 0.01) between groups of cats. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2B: FIV-vaccinated/FIV-uninfected cats (n = 114) according to the time (days) elapsed since the 
last annual FIV vaccination. No significant effect was found (P = 0.42). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2C: FIV-vaccinated/FIV-uninfected cats (n = 114) according to the age of cat at the time of 
sampling (years). No significant effect was found (P = 0.21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2D: FIV-vaccinated/FIV-uninfected cats (n = 114) according to number of annual booster FIV 
vaccinations received. No significant effect was found (P = 0.43). 
 
Figure 3: Summary of FIV antibody test results from the prospective study (Study 2) at various time 
points (n = 12). The FIV target capture antigen/s for each point-of-care antibody test kit is included is 
brackets. A primary FIV vaccination course was administered at 0, 4 and 8 weeks.  
 
 
 
Table 1: Outline of the prospective study design (Study 2), showing time points for three FIV vaccinations (weeks 0, 4 and 8), PCR testing (weeks 
0 and 34) and antibody-testing (up to 11 times between week 0 and 34). Antibody-testing was not performed at weeks 14, 16 or 20 for cats that 
were FIV-negative at week 12 with Witness and Anigen Rapid. 
    
First  
FIV 
vaccine 
2 weeks 
after first 
FIV 
vaccine 
Second 
FIV 
vaccine 
2 weeks 
after 
second FIV 
vaccine 
Third  
FIV 
vaccine 
2 weeks 
after 
final FIV 
vaccine 
4 weeks 
after 
final FIV 
vaccine 
6 weeks 
after 
final FIV 
vaccine 
8 weeks 
after 
final FIV 
vaccine 
12 weeks 
after 
final FIV 
vaccine 
26 weeks 
after 
final FIV 
vaccine 
  In weeks T = 0 2 4 6 8 10 12 14 16 20 34 
  In days T =  0 14 28 42 56 70 84 98 112 140 238 
Diagnostic antibody testing 
           
  
SNAP Combo 
 
● ● ● ● ● ● ● ● ● ● ● 
Witness 
 
● ● ● ● ● ● ● ● ● ● ● 
Anigen Rapid 
 
● ● ● ● ● ● ● ● ● ● ● 
VetScan Rapid 
 
● ● ● ● ● ● ● ● ● ● ● 
IDEXX PCR  
 
● 
         
● 
  
           
  
FIV vaccine - 3 boosters 4 weeks apart  ●   ●   ●        
 
Table 3: Summary of FIV PCR and FIV antibody test results from the prospective study (Study 2) at various time points (n = 12). Four cats were 
withdrawn from the study (see text for details); results from these cats are not included here but are provided in online Supplement 1. 
    
First  
FIV 
vaccine 
2 weeks 
after first 
FIV 
vaccine 
Second 
FIV 
vaccine 
2 weeks 
after 
second FIV 
vaccine 
Third  
FIV 
vaccine 
2 weeks 
after 
final FIV 
vaccine 
4 weeks 
after 
final FIV 
vaccine 
6 weeks 
after 
final FIV 
vaccine 
8 weeks 
after 
final FIV 
vaccine 
12 weeks 
after 
final FIV 
vaccine 
26 weeks 
after 
final FIV 
vaccine 
  In weeks T = 0 2 4 6 8 10 12 14 16 20 34 
  In days T =  0 14 28 42 56 70 84 98 112 140 238 
Diagnostic antibody testing 
           
  
SNAP Combo 
 
0/12 7/12 11/12 12/12 12/12 12/12 12/12 3/3 1/1 1/1 12/12 
Witness 
 
0/12 2/12 7/12 8/12 6/12 6/12 2/12 2/3 1/1 0/1 0/12 
Anigen Rapid 
 
0/12 0/12 1/12 7/12 5/12 4/12 2/12 1/3 1/1 0/1 0/12 
VetScan Rapid 
 
0/12 0/12 3/12 12/12 12/12 12/12 12/12 3/3 1/1 1/1 10/12 
IDEXX PCR  
 
0/12          0/12 
                 
 
Online Supplement 1: Summary of FIV PCR and FIV antibody test results from the prospective study (Study 2) at various time points (n = 16), 
including four cats withdrawn from the study at various time points (after weeks 0, 4, 20 and 34). 
    
First  
FIV 
vaccine 
2 weeks 
after first 
FIV 
vaccine 
Second 
FIV 
vaccine 
2 weeks 
after 
second FIV 
vaccine 
Third  
FIV 
vaccine 
2 weeks 
after 
final FIV 
vaccine 
4 weeks 
after 
final FIV 
vaccine 
6 weeks 
after 
final FIV 
vaccine 
8 weeks 
after 
final FIV 
vaccine 
12 weeks 
after 
final FIV 
vaccine 
26 weeks 
after 
final FIV 
vaccine 
  In weeks T = 0 2 4 6 8 10 12 14 16 20 34 
  In days T =  0 14 28 42 56 70 84 98 112 140 238 
Diagnostic antibody testing 
           
  
SNAP Combo 
 
0/16 10/15 14/15 14/14 14/14 14/14 14/14 5/5 3/3 3/3 13/13 
Witness 
 
0/16 3/15 9/15 10/14 8/14 8/14 3/14 3/5 2/3 1/3 0/13 
Anigen Rapid 
 
1/16 1/15 2/15 9/14 7/14 6/14 4/14 3/5 2/3 1/3 1/13 
VetScan Rapid 
 
0/16 1/15 4/15 14/14 14/14 14/14 14/14 5/5 3/3 3/3 11/13 
IDEXX PCR  
 
0/16          0/13 
                 
 
Online Supplement 2: Summary of FIV PCR and FIV antibody test results from the prospective study (Study 2) at various time points for kittens < 
6 months-of-age (n = 4). 
    
First  
FIV 
vaccine 
2 weeks 
after first 
FIV 
vaccine 
Second 
FIV 
vaccine 
2 weeks 
after 
second FIV 
vaccine 
Third  
FIV 
vaccine 
2 weeks 
after 
final FIV 
vaccine 
4 weeks 
after 
final FIV 
vaccine 
6 weeks 
after 
final FIV 
vaccine 
8 weeks 
after 
final FIV 
vaccine 
12 weeks 
after 
final FIV 
vaccine 
26 weeks 
after 
final FIV 
vaccine 
  In weeks T = 0 2 4 6 8 10 12 14 16 20 34 
  In days T =  0 14 28 42 56 70 84 98 112 140 238 
Diagnostic antibody testing 
           
  
SNAP Combo 
 
0/4 3/4 4/4 4/4 4/4 4/4 4/4 1/1 0/0 0/0 4/4 
Witness 
 
0/4 1/4 1/4 2/4 2/4 2/4 0/4 0/1 0/0 0/0 0/4 
Anigen Rapid 
 
0/4 0/4 0/4 1/4 1/4 1/4 1/4 0/1 0/0 0/0 0/4 
VetScan Rapid 
 
0/4 0/4 0/4 4/4 4/4 4/4 4/4 1/1 0/0 0/0 4/4 
IDEXX PCR  
 
0/4          0/4 
                 
 
Online Supplement 3: Summary of FIV PCR and FIV antibody test results from the prospective study (Study 2) at various time points for cats > 6 
months-of-age (n = 8). 
    
First  
FIV 
vaccine 
2 weeks 
after first 
FIV 
vaccine 
Second 
FIV 
vaccine 
2 weeks 
after 
second FIV 
vaccine 
Third  
FIV 
vaccine 
2 weeks 
after 
final FIV 
vaccine 
4 weeks 
after 
final FIV 
vaccine 
6 weeks 
after 
final FIV 
vaccine 
8 weeks 
after 
final FIV 
vaccine 
12 weeks 
after 
final FIV 
vaccine 
26 weeks 
after 
final FIV 
vaccine 
  In weeks T = 0 2 4 6 8 10 12 14 16 20 34 
  In days T =  0 14 28 42 56 70 84 98 112 140 238 
Diagnostic antibody testing 
           
  
SNAP Combo 
 
0/8 4/8 7/8 8/8 8/8 8/8 8/8 2/2 1/1 1/1 8/8 
Witness 
 
0/8 1/8 6/8 6/8 4/8 4/8 2/8 2/2 1/1 0/1 0/8 
Anigen Rapid 
 
0/8 0/8 1/8 6/8 4/8 3/8 1/8 1/2 1/1 0/1 0/8 
VetScan Rapid 
 
0/8 8/8 3/8 8/8 8/8 8/8 8/8 2/2 1/1 1/1 6/8 
IDEXX PCR  
 
0/8          0/8 
                 
 
